Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir/pibrentasvir - AbbVie

Next Previous
Drug Profile

Glecaprevir/pibrentasvir - AbbVie

Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; Glecaprevir Hydrate/Pibrentasvir - AbbVie; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir; Pibrentasvir/glecaprevir-Abbvie

Latest Information Update: 17 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 22 May 2026 AbbVie expects the final European Commission decision on the approval of Glecaprevir/pibrentasvir (MAVIRET®) in Hepatitis C infection (HCV) (In adults, In the elderly, In adolescents, In children) by the third quarter of 2026
  • 22 May 2026 Preregistration for Hepatitis C (In adults, In the elderly, In adolescents, In children) in European Union (PO)
  • 22 May 2026 The Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency adopts a positive opinion recommending the approval of Glecaprevir/pibrentasvir (MAVIRET®) in Hepatitis C (In adults, In the elderly, In adolescents, In children)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top